Welcome to our dedicated page for Lesaka Tech SEC filings (Ticker: LSAK), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Tracking how a South-African fintech balances high-volume merchant transactions with consumer micro-loans isn’t simple. Lesaka Tech’s dual-segment model packs every 10-K annual report with dense tables on processing fees, loan impairments, and prepaid airtime revenue. Finding those numbers—or spotting when insiders buy shares—can feel like leafing through a phone book.
That’s why Stock Titan pairs each document with AI-powered summaries. Wondering how an acquisition affects revenue? Our engine flags the exact Lesaka Tech 8-K material events explained section. Need the latest Lesaka Tech quarterly earnings report 10-Q filing? It arrives within minutes of hitting EDGAR, already distilled into segment trends you can scan in seconds.
The platform covers every form investors ask for:
- Lesaka Tech insider trading Form 4 transactions—real-time alerts track executive buys and sells so you can study Lesaka Tech executive stock transactions Form 4 before markets react.
- Lesaka Tech proxy statement executive compensation—AI highlights performance targets and option grants, letting you assess alignment at a glance.
- Lesaka Tech annual report 10-K simplified—risk factors on South-African payment regulation translated into plain English.
Use cases professionals rely on: compare quarter-over-quarter take-rate shifts, monitor credit-loss trends, and benchmark insider sentiment—all without hunting through hundreds of pages. Put simply, Lesaka Tech SEC filings explained simply. From Lesaka Tech earnings report filing analysis to Lesaka Tech insider transactions real-time, Stock Titan keeps you ahead by understanding Lesaka Tech SEC documents with AI.
Kronos Bio, Inc. (KRON) filed a Form 15-12G with the U.S. SEC on 30 June 2025, certifying the termination of registration of its common stock under Section 12(g) of the Securities Exchange Act of 1934 and suspending the company’s duty to file reports under Sections 13 and 15(d).
The company relied on Rule 12g-4(a)(1) and Rule 12h-3(b)(1)(i), disclosing an approximate holder count of one. No other securities remain subject to reporting obligations. The notice was signed by Chief Financial Officer Michael Hearne.
Once the Form 15 becomes effective, Kronos Bio will no longer submit periodic filings such as Forms 10-K, 10-Q or 8-K, significantly reducing public disclosure and potentially affecting liquidity for remaining shareholders.
Mali Lincoln Camagu, CEO of Southern Africa and Director at Lesaka Technologies (LSAK), reported a disposition of 12,396 shares of common stock on November 17, 2024. The transaction was coded as 'F', indicating a payment of exercise price or tax liability using securities.
The shares were disposed of at a price of $4.89, which was calculated based on the company's closing price on the Johannesburg Stock Exchange (ZAR 88.25) converted at the exchange rate of $1:ZAR18.06. Following the transaction, Camagu continues to directly own 408,461 shares.
The disposed shares were part of a larger restricted stock grant of 82,639 shares awarded in October 2023, subject to specific stock price-based vesting conditions. This Form 4 filing, signed on June 24, 2025, represents a standard tax-related disposition of shares to cover tax obligations related to the vesting of restricted stock.